Zhi Tong Cai Jing·2025-08-29 03:37Group 1 - Company reported a revenue of 2.433 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 44.73% [1] - Gross profit reached 2.103 billion USD, up 48.33% year-on-year [1] - Net profit was 95.59 million USD, a turnaround from a net loss of 372 million USD in the same period last year, with basic earnings per share of 0.07 USD [1] Group 2 - Company signed a royalty purchase agreement with Royalty Pharma, receiving an upfront payment of 885 million USD for the rights to Tarlatamab outside of China [2] - The transaction is expected to secure 950 million USD in cash flow from Tarlatamab, covering nearly 80% of the 1.25 billion USD development costs committed in partnership with Amgen [2] - The deal is anticipated to strengthen the company's balance sheet and enhance operational and strategic flexibility, supporting ongoing innovation pipeline development [2]